CAJ | 학술논문

T细胞性急性淋巴细胞白血病（ T-ALL）预后差，易早期复发，寻找安全有效的治疗手段成为临床研究热点。特异性免疫治疗及靶向基因治疗克服了传统化疗药物的非靶向性，为解决化疗对正常细胞和机体损伤较大的问题提供了可能。本文对Campath-1H、Dachzumab、抗原特异性细胞毒性 T细胞（ CTL）等特异性免疫治疗及阻断Lmo2基因、FMS样酪氨酸激酶-3（FLT3）、Bcl-2相互作用的细胞凋亡调节因子（Bim）和Notch1等靶向基因治疗T-ALL进行综述，阐述其抗T-ALL细胞的作用机制和相关临床试验，为T-ALL的治疗提供参考和新的研究思路。
T세포성급성림파세포백혈병（ T-ALL）예후차，역조기복발，심조안전유효적치료수단성위림상연구열점。특이성면역치료급파향기인치료극복료전통화료약물적비파향성，위해결화료대정상세포화궤체손상교대적문제제공료가능。본문대Campath-1H、Dachzumab、항원특이성세포독성 T세포（ CTL）등특이성면역치료급조단Lmo2기인、FMS양락안산격매-3（FLT3）、Bcl-2상호작용적세포조망조절인자（Bim）화Notch1등파향기인치료T-ALL진행종술，천술기항T-ALL세포적작용궤제화상관림상시험，위T-ALL적치료제공삼고화신적연구사로。
T-cell acute lymphoblastic leukemia( T-ALL)has poor prognosis and early relapse,which makes it a research hotspot to find safe and effective therapies. Specific immunotherapy and targeted gene therapy have the superiority of killing T-ALL cells without injuring normal cells and body compared with the traditional chemotherapy drugs. The article made a review of specific immunotherapy,such as Campath-1H,Dachzumab and CTL,and targeted gene therapy,such as blocking Lmo2,FLT3,Bim and Notch1 on T-ALL and illustrated the mechanism and relevant clinical trials,in order to provide a reference for the treatment of T-ALL and new thoughts for relevant research.